Gene Expression Regulation, Leukemic
"Gene Expression Regulation, Leukemic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
Descriptor ID |
D015973
|
MeSH Number(s) |
G05.308.370.500
|
Concept/Terms |
Gene Expression Regulation, Leukemic- Gene Expression Regulation, Leukemic
- Regulation of Gene Expression, Leukemic
- Regulation, Gene Expression, Leukemic
- Leukemic Gene Expression Regulation
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Leukemic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Leukemic".
This graph shows the total number of publications written about "Gene Expression Regulation, Leukemic" by people in this website by year, and whether "Gene Expression Regulation, Leukemic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 1 | 3 |
1995 | 2 | 2 | 4 |
1996 | 5 | 1 | 6 |
1997 | 2 | 0 | 2 |
1998 | 1 | 1 | 2 |
1999 | 1 | 0 | 1 |
2000 | 2 | 0 | 2 |
2001 | 0 | 2 | 2 |
2002 | 1 | 0 | 1 |
2003 | 0 | 2 | 2 |
2004 | 2 | 2 | 4 |
2005 | 4 | 1 | 5 |
2006 | 2 | 7 | 9 |
2007 | 2 | 5 | 7 |
2008 | 6 | 7 | 13 |
2009 | 7 | 6 | 13 |
2010 | 8 | 4 | 12 |
2011 | 8 | 8 | 16 |
2012 | 2 | 6 | 8 |
2013 | 3 | 10 | 13 |
2014 | 5 | 5 | 10 |
2015 | 3 | 9 | 12 |
2016 | 7 | 14 | 21 |
2017 | 4 | 9 | 13 |
2018 | 9 | 5 | 14 |
2019 | 2 | 7 | 9 |
2020 | 2 | 4 | 6 |
2021 | 2 | 4 | 6 |
2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gene Expression Regulation, Leukemic" by people in Profiles.
-
CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells. Nat Commun. 2022 01 31; 13(1):587.
-
Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J. 2022 01 11; 12(1):5.
-
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood. 2021 11 11; 138(19):1885-1895.
-
RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia. 2022 03; 36(3):712-722.
-
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021 07 08; 138(1):71-85.
-
DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia. Sci Rep. 2021 06 09; 11(1):12148.
-
Loss of expression of both miR-15/16 loci in CML transition to blast crisis. Proc Natl Acad Sci U S A. 2021 03 16; 118(11).
-
Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia. Clin Epigenetics. 2021 01 28; 13(1):21.
-
CD123 Expression in Philadelphia Chromosome-like B Acute Lymphoblastic Leukemia/Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):e317-e320.
-
Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423.